Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study

Eur Urol. 2022 Jun;81(6):622. doi: 10.1016/j.eururo.2022.02.017. Epub 2022 Mar 10.

Authors

Markus Grabbert¹, Anca L Grosu², Constantinos Zamboglou³, Christian Gratzke⁴

Affiliations

¹ Department of Urology, University Hospital Freiburg, Freiburg, Germany.
² Department of Radiotherapy, University Hospital Freiburg, Freiburg, Germany.
³ Department of Radiotherapy, University Hospital Freiburg, Freiburg, Germany; German Oncology Center, European University, Limassol, Cyprus.
⁴ Department of Urology, University Hospital Freiburg, Freiburg, Germany. Electronic address: christian.gratzke@uniklinik-freiburg.de.

PMID: 35282968
DOI: 10.1016/j.eururo.2022.02.017

No abstract available

Publication types

Clinical Trial, Phase II

MeSH terms

Carcinoma, Renal Cell* / pathology
Carcinoma, Renal Cell* / therapy
Clinical Trials, Phase II as Topic
Combined Modality Therapy
Humans
Kidney Neoplasms* / pathology
Kidney Neoplasms* / therapy
Nivolumab / therapeutic use
Radiosurgery

Substances

Nivolumab